HRP20230894T1 - Režimi i postupci liječenja multiple skleroze ofatumumabom - Google Patents
Režimi i postupci liječenja multiple skleroze ofatumumabom Download PDFInfo
- Publication number
- HRP20230894T1 HRP20230894T1 HRP20230894TT HRP20230894T HRP20230894T1 HR P20230894 T1 HRP20230894 T1 HR P20230894T1 HR P20230894T T HRP20230894T T HR P20230894TT HR P20230894 T HRP20230894 T HR P20230894T HR P20230894 T1 HRP20230894 T1 HR P20230894T1
- Authority
- HR
- Croatia
- Prior art keywords
- ofatumumab
- multiple sclerosis
- use according
- administered
- relapsing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Pressure Welding/Diffusion-Bonding (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374986P | 2016-08-15 | 2016-08-15 | |
| EP20180938.1A EP3733712B1 (en) | 2016-08-15 | 2017-08-11 | Regimens and methods of treating multiple sclerosis using ofatumumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230894T1 true HRP20230894T1 (hr) | 2023-11-24 |
Family
ID=59901554
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230894TT HRP20230894T1 (hr) | 2016-08-15 | 2017-08-11 | Režimi i postupci liječenja multiple skleroze ofatumumabom |
| HRP20201388TT HRP20201388T1 (hr) | 2016-08-15 | 2017-08-11 | Režimi i postupci liječenja multiple skleroze uporabom ofatumumaba |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201388TT HRP20201388T1 (hr) | 2016-08-15 | 2017-08-11 | Režimi i postupci liječenja multiple skleroze uporabom ofatumumaba |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US11161909B2 (https=) |
| EP (5) | EP3497132B1 (https=) |
| JP (2) | JP6851391B2 (https=) |
| KR (2) | KR20190038914A (https=) |
| CN (5) | CN120053638A (https=) |
| AU (2) | AU2017311664C1 (https=) |
| CA (2) | CA3030530C (https=) |
| CY (1) | CY1123350T1 (https=) |
| DE (1) | DE202017007542U1 (https=) |
| DK (2) | DK3497132T3 (https=) |
| ES (2) | ES2954259T3 (https=) |
| FI (1) | FI3733712T3 (https=) |
| HR (2) | HRP20230894T1 (https=) |
| HU (2) | HUE051948T2 (https=) |
| IL (4) | IL302488B2 (https=) |
| LT (2) | LT3497132T (https=) |
| MX (1) | MX388593B (https=) |
| PL (2) | PL3497132T3 (https=) |
| PT (2) | PT3497132T (https=) |
| RS (2) | RS64541B1 (https=) |
| RU (1) | RU2749951C2 (https=) |
| SI (2) | SI3497132T1 (https=) |
| TW (1) | TWI752995B (https=) |
| WO (1) | WO2018033841A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120053638A (zh) * | 2016-08-15 | 2025-05-30 | 诺华股份有限公司 | 使用奥法木单抗治疗多发性硬化的方案和方法 |
| ES2957112T3 (es) | 2019-09-11 | 2024-01-11 | Novartis Ag | Tratamiento del RMS mediante cambio de terapia |
| MX2022003030A (es) | 2019-09-11 | 2022-04-07 | Novartis Ag | Tratamiento de afecciones distintas de la esclerosis multiple en pacientes tratados con ofatumumab. |
| US20230151106A1 (en) * | 2020-04-09 | 2023-05-18 | Novartis Ag | OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG |
| US20240228647A1 (en) * | 2021-04-14 | 2024-07-11 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4816401A (en) | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
| JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| JP2003529361A (ja) | 2000-03-30 | 2003-10-07 | アムジェン インコーポレイテッド | ＣＤ２０／ＩｇＥレセプター様分子およびその使用 |
| EA013564B1 (ru) | 2000-08-03 | 2010-06-30 | Терапеутик Хьюман Поликлоналз Инк. | Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| DOP2006000029A (es) | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| WO2012018704A1 (en) | 2010-08-02 | 2012-02-09 | Sanofi-Aventis U.S. Llc | Use of teriflunomide for treating multiple sclerosis |
| EP2663331A4 (en) | 2011-01-10 | 2015-07-15 | Glaxosmithkline Intellectual Property Man Ltd | NEW USES |
| TWI606064B (zh) * | 2012-02-08 | 2017-11-21 | Ｉｇｍ生物科技公司 | 細胞死亡誘導分子（ｃｄｉｍ）結合蛋白類及彼等之用途 |
| EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| SG11201500499TA (en) | 2012-08-10 | 2015-03-30 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| WO2015162504A1 (en) | 2014-04-23 | 2015-10-29 | Novartis Ag | Novel dosing and uses of ofatumumab |
| EA201692180A1 (ru) | 2014-04-29 | 2017-08-31 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
| WO2016123329A2 (en) * | 2015-01-28 | 2016-08-04 | Genentech, Inc. | Gene expression markers and treatment of multiple sclerosis |
| CN106699886A (zh) | 2015-07-13 | 2017-05-24 | 西藏海思科药业集团股份有限公司 | 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体 |
| CN120053638A (zh) | 2016-08-15 | 2025-05-30 | 诺华股份有限公司 | 使用奥法木单抗治疗多发性硬化的方案和方法 |
| ES2957112T3 (es) | 2019-09-11 | 2024-01-11 | Novartis Ag | Tratamiento del RMS mediante cambio de terapia |
| MX2022003030A (es) | 2019-09-11 | 2022-04-07 | Novartis Ag | Tratamiento de afecciones distintas de la esclerosis multiple en pacientes tratados con ofatumumab. |
| US20230151106A1 (en) | 2020-04-09 | 2023-05-18 | Novartis Ag | OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG |
| US20240228647A1 (en) | 2021-04-14 | 2024-07-11 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
| IL310813A (en) | 2021-08-16 | 2024-04-01 | Novartis Ag | OFATUMUMAB for the treatment of multiple sclerosis in children |
-
2017
- 2017-08-11 CN CN202510270941.5A patent/CN120053638A/zh active Pending
- 2017-08-11 PT PT177688637T patent/PT3497132T/pt unknown
- 2017-08-11 KR KR1020197007454A patent/KR20190038914A/ko not_active Ceased
- 2017-08-11 EP EP17768863.7A patent/EP3497132B1/en active Active
- 2017-08-11 EP EP23172507.8A patent/EP4252847A3/en active Pending
- 2017-08-11 LT LTEP17768863.7T patent/LT3497132T/lt unknown
- 2017-08-11 HU HUE17768863A patent/HUE051948T2/hu unknown
- 2017-08-11 WO PCT/IB2017/054909 patent/WO2018033841A1/en not_active Ceased
- 2017-08-11 RU RU2019107146A patent/RU2749951C2/ru active
- 2017-08-11 MX MX2019001860A patent/MX388593B/es unknown
- 2017-08-11 FI FIEP20180938.1T patent/FI3733712T3/fi active
- 2017-08-11 DE DE202017007542.3U patent/DE202017007542U1/de active Active
- 2017-08-11 EP EP20180938.1A patent/EP3733712B1/en active Active
- 2017-08-11 HR HRP20230894TT patent/HRP20230894T1/hr unknown
- 2017-08-11 CA CA3030530A patent/CA3030530C/en active Active
- 2017-08-11 RS RS20230635A patent/RS64541B1/sr unknown
- 2017-08-11 IL IL302488A patent/IL302488B2/en unknown
- 2017-08-11 AU AU2017311664A patent/AU2017311664C1/en active Active
- 2017-08-11 ES ES20180938T patent/ES2954259T3/es active Active
- 2017-08-11 PL PL17768863T patent/PL3497132T3/pl unknown
- 2017-08-11 CN CN202510270903.XA patent/CN120037367A/zh active Pending
- 2017-08-11 EP EP25225892.6A patent/EP4711008A2/en active Pending
- 2017-08-11 HU HUE20180938A patent/HUE063625T2/hu unknown
- 2017-08-11 ES ES17768863T patent/ES2821924T3/es active Active
- 2017-08-11 DK DK17768863.7T patent/DK3497132T3/da active
- 2017-08-11 PT PT201809381T patent/PT3733712T/pt unknown
- 2017-08-11 CA CA3101514A patent/CA3101514A1/en active Pending
- 2017-08-11 KR KR1020207034140A patent/KR20200136503A/ko not_active Ceased
- 2017-08-11 SI SI201730400T patent/SI3497132T1/sl unknown
- 2017-08-11 CN CN202510270924.1A patent/CN120000782A/zh active Pending
- 2017-08-11 IL IL313932A patent/IL313932A/en unknown
- 2017-08-11 IL IL276890A patent/IL276890B2/en unknown
- 2017-08-11 DK DK20180938.1T patent/DK3733712T3/da active
- 2017-08-11 SI SI201731396T patent/SI3733712T1/sl unknown
- 2017-08-11 EP EP24166956.3A patent/EP4371611A3/en active Pending
- 2017-08-11 HR HRP20201388TT patent/HRP20201388T1/hr unknown
- 2017-08-11 CN CN201780049932.7A patent/CN109641965A/zh active Pending
- 2017-08-11 PL PL20180938.1T patent/PL3733712T3/pl unknown
- 2017-08-11 CN CN202510270961.2A patent/CN120053639A/zh active Pending
- 2017-08-11 US US16/324,619 patent/US11161909B2/en active Active
- 2017-08-11 JP JP2018550539A patent/JP6851391B2/ja active Active
- 2017-08-11 RS RS20201066A patent/RS60807B1/sr unknown
- 2017-08-11 LT LTEP20180938.1T patent/LT3733712T/lt unknown
- 2017-08-15 TW TW106127565A patent/TWI752995B/zh active
-
2019
- 2019-02-12 IL IL264804A patent/IL264804B/en active IP Right Grant
-
2020
- 2020-02-07 JP JP2020019337A patent/JP7198786B2/ja active Active
- 2020-02-17 AU AU2020201112A patent/AU2020201112C1/en active Active
- 2020-09-11 CY CY20201100861T patent/CY1123350T1/el unknown
-
2021
- 2021-10-06 US US17/495,559 patent/US20220081488A1/en not_active Abandoned
-
2023
- 2023-06-08 US US18/331,701 patent/US12570754B2/en active Active
-
2024
- 2024-03-06 US US18/597,624 patent/US12338290B2/en active Active
-
2025
- 2025-05-28 US US19/221,422 patent/US20250289902A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230894T1 (hr) | Režimi i postupci liječenja multiple skleroze ofatumumabom | |
| HRP20191162T1 (hr) | Postupci liječenja ankilozantnog spondilitisa uporabom anti-il-17 protutijela | |
| JP2019065028A5 (https=) | ||
| HRP20180301T1 (hr) | Postupci liječenja psorijaze uporabom il-17 antagonista | |
| HRP20241717T1 (hr) | Postupci liječenja ili prevencije migrenske glavobolje korištenjem protutijela usmjerenih na cgrp receptor | |
| HRP20200072T1 (hr) | Načini doziranja za spojeve klase ehinokandina | |
| JP2013509435A5 (https=) | ||
| PE20190205A1 (es) | Uso de inhibidores de miostatina y terapias de combinacion | |
| AR109494A1 (es) | Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos | |
| IL309340A (en) | Dosing regimen for missing doses of paliperidone long-acting injectable esters | |
| JP2012180381A5 (https=) | ||
| HRP20221139T1 (hr) | Stabilizirane formulacije koje sadrže antitijela protiv interleukin-6 receptora (il-6r) | |
| HRP20151350T1 (hr) | Neuroprotekcija kod demijelinizacijskih bolesti | |
| EA201270167A1 (ru) | Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения | |
| JP2016505572A5 (https=) | ||
| MX2021001083A (es) | Regimen posologico para anticuerpos biespecificos contra bcma-cd3. | |
| HRP20211371T1 (hr) | Stabilne, vodene formulacije protutijela | |
| JP2015534562A5 (https=) | ||
| FI3284480T3 (fi) | IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi | |
| HRP20210207T1 (hr) | Uporaba protutijela anti-sklerostin u liječenju osteogenesis imperfecta | |
| RU2015119603A (ru) | Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc | |
| HRP20201632T1 (hr) | Režimi doziranja melflufena kod raka | |
| FI2683245T4 (fi) | Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä | |
| CY1120176T1 (el) | Μεθοδος για τη μειωση των συμπτωματων που μοιαζουν με αυτα της γριπης που συνδεονται με ενδομυϊκη χορηγηση ιντερφερονης με τη χρηση ενος σχηματος κλιμακουμενης δοσολογιας ταχειας τιτλοδοτησης | |
| JP2016515137A5 (https=) |